ALERT: Your health is top priority. We’re committed to providing reliable COVID-19 resources to keep you informed and safe.

Januvia and Janumet Side Effects

Januvia and Janumet are similar medications used in the treatment of Type 2 diabetes. Common side effects include headache and flu-like symptoms. Some of the potential serious side effects include lactic acidosis, heart problems and pancreatitis.

Doctors prescribe Januvia (sitagliptin) and Janumet (sitagliptin and metformin) to treat Type 2 diabetes along with diet and exercise. Janumet also has an extended release formula called Janumet XR.

In general, most reactions to Januvia and Janumet are mild. The most common side effects are headache, runny nose, sore throat and upper respiratory tract infections, according to the drugs’ maker, Merck & Co. Inc.

Other reported side effects include hypoglycemia (low blood sugar), stomach problems, allergic reactions and bullous pemphigoid, a rare skin rash with blisters and erosions (skin breakdown).

In addition, Janumet combines the active ingredient in Januvia, sitagliptin, with metformin so it has side effects from both drugs. The most common side effect of metformin is diarrhea.

Along with the minor, common side effects, these drugs also have more rare and serious side effects such as pancreatitis — inflammation of the pancreas — risk of heart failure and severe joint pain. Some of these side effects led people to file lawsuits against Merck.

Janumet has a black box warning — the U.S. Food and Drug Administration’s most serious warning — for lactic acidosis linked to metformin.

From 2006 to Dec. 5, 2019, the FDA’s Adverse Events Reporting System (FAERS) received 25,540 adverse events reports for Januvia. Of those reports, 12,537 were serious, including 2,421 deaths. The most reported problems were gastrointestinal disorders, including pancreatitis. However, reporting these adverse events to the FDA does not mean that they were caused by Januvia.

For Janumet and Janumet XR, there were 7,745 adverse events. Of those reports, 5,018 were serious, including 1,161 deaths. Like Januvia, the most reported problems were gastrointestinal disorders. However, Janumet may not have caused these adverse events.

Pancreatitis and Pancreatic Cancer

Some studies have linked Janumet and Januvia to pancreatitis, or inflammation of the pancreas. The condition may lead to abdominal and back pain, nausea, vomiting, fever, irregular pulse and weight loss, according to the National Institute of Diabetes and Digestive and Kidney Diseases. The FDA requires Merck to warn about pancreatitis in the drugs’ labels.

A 2013 study in JAMA Internal Medicine found people who used sitagliptin had double the risk of acute pancreatitis. The FDA had already flagged acute pancreatitis as a problem with Januvia early on. It required Merck to conduct additional studies to assess the risk.

These results were due by June 15, 2011, but the FDA rejected Merck’s initial study designs as inadequate, Medpage Today reported. The company did not follow up until the FDA sent them a warning letter more than a year later.

Did You Know?
Studies have found sitagliptin — the active ingredient in Januvia and Janumet — may increase the risk of acute pancreatitis.
Source: FDA Drug Safety Communication

The FDA began investigating new reports of possible increased risk of pancreatitis and pancreatic cancer from Januvia and other drugs in its class in March 2013. The FDA had become aware of new findings that examined “a small number of pancreatic tissue specimens taken from patients after they died from unspecified causes.” The  findings suggested an increased risk of pancreatitis and pre-cancerous cellular changes in patients taking the drugs, according to the FDA.

So far, no studies have found a definitive link between Januvia, Janumet and pancreatic cancer.

In 2017, Diabetes Care published the findings of a large study on the pancreatic safety of sitagliptin. Researchers found a small increase in pancreatic risk and said pancreatitis and pancreatic cancer were “uncommon” in people taking the drug.

Out of 7,332 people who took sitagliptin, 23 developed acute pancreatitis. Four of those cases were severe, and two of the patients died. Out of 7,339 people who took placebo, 12 developed acute pancreatitis.  Authors of the study found cancer occurred more in people who took a placebo versus those who took sitagliptin.

Merck cautions that pancreatitis is a serious side effect of Januvia and Janumet that can lead to death. Patients should tell their doctor immediately if they have severe pain in their stomach area that won’t go away or that extends to the back.

Before taking these drugs, patients should let their doctor know if they’ve had pancreatitis in the past. It is not known whether people with a history of pancreatitis are in greater danger of developing the condition while taking the drugs.

Sitagliptin and Heart Failure

Merck added a warning about the risk of heart failure to Januvia and Janumet labels in August 2017. The manufacturer says doctors should consider the risks and benefits in patients at risk for heart failure. People with kidney problems are at greater risk of heart failure when taking Januvia and Janumet.

The label change followed a 2016 FDA safety announcement in which the agency said it was adding warnings about heart failure risk to labels of medicines containing saxagliptin and alogliptin (Nesina, Kazano and Oseni). The FDA had evaluated two large clinical studies that showed more patients who took the drugs were admitted to the hospital for heart failure compared to patients who took a placebo.

The agency cautioned patients taking these drugs to contact their doctor immediately if they develop signs of heart failure, including: unusual shortness of breath during routine activities; tiredness, weakness, or fatigue; trouble breathing when reclining; or weight gain with swelling in the ankles, feet, legs or stomach.

Cardiac Disorders Reported
From 2006 to December 5, 2019, the FDA received 1,471 reports of cardiac disorders in people who took Januvia. Reports included congestive heart failure. However, these adverse events may not have been caused by Januvia.
Source: FDA Adverse Events Reporting System (FAERS) Public Dashboard

However, studies on the topic have had mixed results.

For example, a large-scale clinical trial funded by Merck found no increased risk of major cardiovascular events or hospitalization with heart failure. Results of the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) were published in the New England Journal of Medicine in 2015.

But an independent 2016 Taiwanese study by C.H. Tseng published in Oncotarget found “sitagliptin increases the risk of heart failure hospitalization within one year of use, but reduces the risk thereafter.”

Severe Joint Pain

In 2015, the FDA required Merck and other makers of dipeptidyl peptidase-4 (DPP-4) inhibitors to add warnings for severe joint pain to the drugs’ labels. The agency said in its Drug Safety Communication that the pain could be “severe and disabling.”

While the FDA warned that all DPP-4 inhibitors could cause joint pain, sitagliptin accounted for the most reports. In 2015, the drug constituted 80 percent of all U.S. prescriptions for the DPP-4 class, Medpage Today reported.

The FDA found 33 cases of joint pain from the time it approved the first DPP-4 inhibitor on Oct. 16, 2006 through December 2013. Twenty-eight of those cases were in people who took sitagliptin. The next highest number of joint pain cases was five with saxagliptin (Onglyza).

In two thirds of the cases, patients experienced pain within one month of starting the drugs. Ten patients ended up in the hospital.

Nearly 70 percent of the time, the symptoms went away in less than a month after the patients stopped taking the medicine. Merck advises people who experience joint pain to talk to their doctors about discontinuing the drug.

Skin Problems

Januvia and Janumet include warnings for bullous pemphigoid, a chronic blistering disease that causes inflammation in the skin. The skin condition may last months or years — even with treatment — and can be fatal.

Merck has received reports of people who used a DPP-4 inhibitor and needed to be hospitalized for bullous pemphigoid. In the reported cases, the symptoms generally went away when patients stopped taking the drug and received topical or systemic immunosuppressive treatment.

In studies, most cases of bullous pemphigoid occurred in people who took DPP-4 inhibitors Galvus (not sold in the U.S.) and Tradjenta. Both drugs increase the risk for the skin condition. Januvia was not associated with the same level of risk.

However, there have been some cases of the side effect in people who took Januvia. For instance, Akihiro Hattori and colleagues reported one case involving an 87-year-old woman in the Journal of the Japan Diabetes Society.

Patient Story
One month after first taking sitagliptin, an 87-year-old woman developed lesions and blisters that needed to be treated in a hospital.
Source: Journal of the Japan Diabetes Society

About one month after the woman began taking sitagliptin, she was admitted to the hospital with bulls-eye-shaped lesions on her lower legs. After five days in the hospital, the woman developed blisters on her palms and thighs.

Doctors diagnosed her with bullous pemphigoid and treated her with steroid therapy. They also stopped giving her sitagliptin, and she recovered.

Merck cautions patients to tell their doctor if they develop blisters or erosions (skin breakdown) while taking Janumet or Januvia.

Lactic Acidosis with Janumet

Metformin in Janumet can cause lactic acidosis, a serious condition caused by too much lactic acid in the blood, with symptoms such as malaise (feeling tired), body aches, breathing problems and abdominal pain. It can result in death, hypothermia—low body temperature—and low blood pressure. Janumet has a black box warning for lactic acidosis.

From 2008 to December 5, 2019, FAERS received 244 reports of lactic acidosis and increased lactic acid in people who took Janumet and Janumet XR. However, these adverse events may not have been caused by Janumet and Janumet XR.
Source: FDA Adverse Events Reporting System (FAERS) Public Dashboard

People who suffer lactic acidosis will need hospitalization and should immediately discontinue Janumet. Merck’s medication insert recommends that people on Janumet undergo a procedure called hemodialysis to remove the metformin in the blood and correct the acidosis.

People who have poor kidney function are at the most risk for this condition, according to Janumet’s label. The risk also increases with age.

Januvia Pills
Januvia and Janumet Side Effects
  1. Black Box Warnings lactic acidosis (Janumet only)
  2. Common Side Effects in Clinical Trials headache, runny nose, upper respiratory infection, sore throat and diarrhea
  3. Serious Side Effects pancreatitis, joint pain and risk of heart failure

Please seek the advice of a medical professional before making health care decisions.

Related Pages
Michelle Llamas, Senior Content Writer
Written By Michelle Llamas Senior Writer

Michelle Llamas has been writing articles and producing podcasts about drugs, medical devices and the FDA for nearly a decade. She focuses on various medical conditions, health policy, COVID-19, LGBTQ health, mental health and women’s health issues. Michelle collaborates with experts, including board-certified doctors, patients and advocates, to provide trusted health information to the public. Some of her qualifications include:

  • Member of American Medical Writers Association (AMWA) and former Engage Committee and Membership Committee member
  • Centers for Disease Control and Prevention (CDC) Health Literacy certificates
  • Original works published or cited in The Lancet, British Journal of Clinical Pharmacology and the Journal for Palliative Medicine
Edited By
Emily Miller
Emily Miller Managing Editor
Medically Reviewed By

22 Cited Research Articles writers follow rigorous sourcing guidelines and cite only trustworthy sources of information, including peer-reviewed journals, court records, academic organizations, highly regarded nonprofit organizations, government reports and interviews with qualified experts. Review our editorial policy to learn more about our process for producing accurate, current and balanced content.

  1. DailyMed. (2019, August 12). Januvia-sitagliptin tablet, film coated. Retrieved from
  2. DailyMed. (2019, August 12). Janumet – sitagliptin and metformin hydrochloride tablet, film coated. Retrieved from
  3. Merck. (n.d.) Januvia. Retrieved from
  4. Merck. (n.d.) Medication Guide: Januvia. Retrieved from
  5. U.S. Food and Drug Administration. (n.d.). FDA Adverse Event Reporting System (FAERS) Public Dashboard. Retrieved from
  6. Buse, J.B. et al. (2017). Pancreatic Safety of Sitagliptin in the TECOS Study. Retrieved from
  7. U.S. Food and Drug Administration. (2013, March 14). FDA Drug Safety Communication: FDA investigating reports of possible increased risk of pancreatitis and pre-cancerous findings of the pancreas from incretin mimetic drugs for type 2 diabetes. Retrieved from
  8. Egan, AG. (2014, February 27). Pancreatic safety of incretin-based drugs—FDA and EMA assessment. Retrieved from
  9. Singh, S. et al. (2013). Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. Retrieved from
  10. Tucker, M.E. (2018, August 8). Type 2 Diabetes Drugs Linked to Bullous Pemphigoid. Retrieved from
  11. Hattori, A. et al. (2013). A Case of Bullous Pemphigoid Associated with Sitagliptin Treatment. Retrieved from
  12. Gever, J. (2012, February 29). FDA Slaps Merck in Skipped Januvia Study. Retrieved from
  13. Krittanawong, C. et al. (2016). Sitagliptin and Risk of Heart Failure in Patients With Type 2 Diabetes. Retrieved from
  14. Wang, K.L. et al. (2014). Sitagliptin and the risk of hospitalization for heart failure: a population-based study. Retrieved from
  15. Tseng, C.H. (2016). Sitagliptin and heart failure hospitalization in patients with type 2 diabetes. Retrieved from
  16. Tucker, M. (2016, April 5). FDA Warns of Heart-Failure Risk With Two Diabetes Drugs. Retrieved from
  17. Green, J.B. et al. (2015). Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. Retrieved from
  18. U.S. Food and Drug Administration. (2015, August 28). FDA Drug Safety Communication: FDA warns that DPP-4 inhibitors for type 2 diabetes may cause severe joint pain. Retrieved from
  19. Lowes, R. (2015, August 28). DPP-4 Inhibitors for Diabetes Can Cause Severe Joint Pain, FDA Says. Retrieved from
  20. National Institute of Diabetes and Digestive and Kidney Diseases (2019). Pancreatitis. Retrieved from
  21. U.S. Food and Drug Administration (2016, April 5). FDA Drug Safety Communication: FDA adds warnings about heart failure risk to labels of type 2 diabetes medicines containing saxagliptin and alogliptin. Retrieved from
  22. Lee, SG (2019, February 1). Association of dipeptidyl peptidase 4 inhibitor use with risk of bullous pemphigoid in patients with diabetes. Retrieved from
View All Sources
Who Am I Calling?

Calling this number connects you with a Drugwatch representative. We will direct you to one of our trusted legal partners for a free case review.

Drugwatch's trusted legal partners support the organization's mission to keep people safe from dangerous drugs and medical devices. For more information, visit our partners page.

(888) 645-1617